Format

Send to

Choose Destination
PLoS One. 2015 Oct 13;10(10):e0140418. doi: 10.1371/journal.pone.0140418. eCollection 2015.

Microfibrillar-Associated Protein 4: A Potential Biomarker for Screening for Liver Fibrosis in a Mixed Patient Cohort.

Author information

1
Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Department of Clinical Immunology, Naestved Hospital, Naestved, Denmark.
2
Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.
3
Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
4
Department of Biostatistics, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
5
Department of Clinical Immunology, Odense University Hospital, Odense, Denmark; Odense Patient data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark.

Abstract

BACKGROUND AND AIMS:

A method for assessment of liver fibrosis and cirrhosis without the need for a liver biopsy is desirable. Microfibrillar-associated protein 4 (MFAP4) is a suggested biomarker for identification of high-risk patients with severe fibrosis stages. This study aimed to examine associations between plasma MFAP4 (pMFAP4) and transient elastography or chronic hepatitis C virus infection in drug users and in a mixed patient cohort with increased risk of liver disease. Moreover, the study aimed to identify comorbidities that significantly influence pMFAP4.

METHODS:

pMFAP4 was measured in samples from 351 drug users attending treatment centres and from 248 acutely hospitalized medical patients with mixed diagnoses. Linear and logistic multivariate regression analyses were performed and nonparametric receiver operating characteristic-curves for cirrhosis were used to estimate cut-off points for pMFAP4. Univariate and subgroup analyses were performed using non-parametric methods.

RESULTS:

pMFAP4 increased significantly with liver fibrosis score. pMFAP4 was significantly associated with chronic viral infection in the drug users and with transient elastography in both cohorts. In the mixed patient cohort, pMFAP4 was significantly increased among patients with a previous diagnosis of liver disease or congestive heart failure compared to patients with other diagnoses.

CONCLUSIONS:

pMFAP4 has the potential to be used as an outreach-screening tool for liver fibrosis in drug users and in mixed medical patients. pMFAP4 level is positively associated with transient elastography, but additional studies are warranted to validate the possible use of pMFAP4 in larger cohorts and in combination with transient elastography.

PMID:
26460565
PMCID:
PMC4604125
DOI:
10.1371/journal.pone.0140418
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center